Article
Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998).
Leukemia - 1 Apr 2015
Loughran T P, Zickl L, Olson T L, Wang V, Zhang D, Rajala H L M, Hasanali Z, Bennett J M, Lazarus H M, Litzow M R, Evens A M, Mustjoki S, Tallman M S
Abstract excerpt
Failure to undergo activation-induced cell death due to global dysregulation of apoptosis is the pathogenic hallmark of large granular lymphocyte (LGL) leukemia. Consequently, immunosuppressive agents are rational choices for treatment. This first prospective trial in LGL leukemia was a multicenter, phase 2 clinical trial evaluating methotrexate (MTX) at 10 mg/m(2) orally weekly as initial therapy (step 1)....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.